Lymphangioleiomyomatosis : Searching for potential biomarkers
Revilla-López, Eva (Universitat Autònoma de Barcelona. Departament de Medicina)
Ruiz de Miguel, Victoria (Hospital Universitari Vall d'Hebron. Institut de Recerca)
López-Meseguer, Manuel (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Berastegui García, Cristina (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Boada-Pérez, Meritxell (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Mendoza-Valderrey, Alberto (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Arjona-Peris, Marta (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Zapata-Ortega, Marta (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Monforte, Víctor (Centro de Investigación Biomédica en Red de Enfermedades Respiratorias)
Bravo Masgoret, Carles (Centro de Investigación Biomédica en Red de Enfermedades Respiratorias)
Roman, Antonio (Instituto de Salud Carlos III)
Gómez-Ollés, Susana (Universitat Autònoma de Barcelona. Departament de Medicina)
Sáez-Giménez, Berta (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia)

Date:	2023
Abstract:	Vascular endothelial growth factor-D (VEGF-D) is the most commonly used biomarker for diagnosing lymphangioleiomyomatosis (LAM). However, lung biopsy is often necessary as well; therefore, defining new biomarkers for LAM is crucial. The aim of this study was to describe the diagnostic accuracy of a variety of biomarkers. We assessed 13 analytes in serum related to extracellular matrix remodeling, lymphatic involvement and angiogenesis in a cohort of patients with LAM, comparing them with patients with other cystic lung diseases (OCLD) and healthy women. A scoring method based on the cut-point of each VEGF-D and metalloproteinase-2 (MMP-2) was used to evaluate the diagnostic performance of the marker combination. A total of 97 subjects were recruited: 59 (61%) LAM patients, 18 (19%) OCLD patients, and 20 (20%) healthy female controls. MMP-2 was the only extracellular matrix remodeling biomarker able to differentiate LAM patients from OCLD and healthy patients. Serum MMP-2 was higher in LAM patients [median 578 (465-832) ng/ml] than in patients with OCLD and healthy controls [medians 360 (314-546) and 427 (365-513) ng/ml, respectively (p < 0. 0001)]. The area under ROC curve (AUC) of MMP-2 was 0. 785 and that of VEGF-D 0. 815 (p = 0. 6214). The sensitivity/specificity profiles of each biomarker (54/92% for MMP-2, 59/95% for VEGF-D) yielded a composite score (−6. 36 + 0. 0059 × VEGF-D + 0. 0069 × MMP-2) with higher accuracy than each component alone (AUC 0. 88 and sensitivity/specificity 79/87%). Combining MMP-2 and VEGF-D may increase diagnostic accuracy for LAM.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Lymphangioleiomyomatosis ; Biomarkers ; Serum ; Metalloproteinases ; VEGF-D ; Diagnose
Published in:	Frontiers in Medicine, Vol. 10 (february 2023) , ISSN 2296-858X

DOI: 10.3389/fmed.2023.1079317
PMID: 36817769

9 p, 1.3 MB

The record appears in these collections:
Articles > Research articles
Articles > Published articles